The fast-growing field of nanotheranostics is revolutionizing cancer treatment by allowing for precise diagnosis and targeted therapy at the cellular and molecular levels. These nanoscale platforms provide considerable benefits in oncology, including improved disease and therapy specificity, lower systemic toxicity, and real-time monitoring of therapeutic outcomes. However, nanoparticles' complicated interactions with biological systems, notably the immune system, present significant obstacles for clinical translation. While certain nanoparticles can elicit favorable anti-tumor immune responses, others cause immunotoxicity, including complement activation-related pseudoallergy (CARPA), cytokine storms, chronic inflammation, and organ damage. Traditional toxicity evaluation approaches are frequently time-consuming, expensive, and insufficient to capture these intricate nanoparticle-biological interactions. Artificial intelligence (AI) and machine learning (ML) have emerged as transformational solutions to these problems. This paper summarizes current achievements in nanotheranostics for cancer, delves into the causes of nanoparticle-induced immunotoxicity, and demonstrates how AI/ML may help anticipate and create safer nanoparticles. Integrating AI/ML with modern computational approaches allows for the detection of potentially dangerous nanoparticle qualities, guides the optimization of physicochemical features, and speeds up the development of immune-compatible nanotheranostics suited to individual patients. The combination of nanotechnology with AI/ML has the potential to completely realize the therapeutic promise of nanotheranostics while assuring patient safety in the age of precision medicine.

Nanotechnology is a subject that studies, processes, and applies various functional materials, equipment, and systems, and controls substances on a nanoscale. Nanomedicine refers to its application in diagnosing, treating, preventing, and monitoring various diseases. Drugs administered through eye drops must travel a long distance to avoid various eye barriers reaching the posterior segment of the eye, to achieve the lowest drug level. This review focuses on nanotechnology-based eye disease treatment systems and highlights the obstacles affecting the drug management of eyes and nano-systems for the treatment of eye diseases. This paper summarizes the development prospect of nanotechnology and the challenges it faces in the treatment and diagnosis of ophthalmic diseases, to provide information and new ideas for the implementation of treatment and the development of a refractory eye disease management system.